Kardiovaskulär
High-dose fish oil linked to 43% fewer serious cardiovascular events in hemodialysis patients, trial reports
Von KI berichtet Bild generiert von KI Fakten geprüft
A large international randomized trial found that 4 grams a day of omega-3 fish oil was associated with a 43% lower rate of serious cardiovascular events among adults receiving maintenance hemodialysis. The PISCES study enrolled 1,228 participants at 26 sites in Australia and Canada; results were presented at the American Society of Nephrology’s Kidney Week 2025 and published in The New England Journal of Medicine.
Die brasilianische Anvisa hat am Montag, dem 2. Februar 2026, die Erweiterung der therapeutischen Indikationen für Semaglutid, den Wirkstoff in Wegovy und Ozempic, genehmigt. Wegovy kann nun zur Reduzierung des Risikos von Herzinfarkten und Schlaganfällen bei Erwachsenen mit Herz-Kreislauf-Erkrankungen und Übergewicht eingesetzt werden, während Ozempic für Typ-2-Diabetes im Zusammenhang mit chronischer Nierenerkrankung indiziert ist. Die Behörde prüft auch einen Antrag auf eine orale Version von Wegovy.
Von KI berichtet Fakten geprüft
A comprehensive review in Beverage Plant Research concludes that evidence from human studies most strongly supports an association between tea consumption—particularly green tea—and lower risks of cardiovascular disease, obesity, type 2 diabetes and some cancers, while calling evidence for brain and muscle benefits “promising” but less settled. The authors also caution that bottled and bubble tea products, which can include added sugar and other additives, may blunt tea’s potential advantages.
Researchers at the University of Barcelona have discovered that combining two existing medications, pemafibrate and telmisartan, significantly reduces liver fat in animal models of metabolic dysfunction-associated steatotic liver disease (MASLD). This approach could offer a safer treatment option for the condition, which affects about one in three adults worldwide. The findings highlight the potential of drug repurposing to address a disease with limited current therapies.